Developed in collaboration with Waters and Labcyte, the platform enables applications including high-throughput drug screening and metabolomic profiling.
The company hopes to commercialize the assay, and is pursuing a larger validation study, but may face competitors who have also staked claims for this indication.
Researchers brought together blood transcriptomic, metabolomic, proteomic, and immune cell profiles for dozens of West African and Australasian infants.
Olink is perhaps best known for its proximity extension assay (PEA) technology, which allows for highly sensitive, highly multiplexed protein measurements.
In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.
